RxDoctor Payments Data

Karen McGuire, APRN

Family · Dayton, OHNPI 1831717420

Payments from drug & device makers

$1,458in general payments, 2019–2025

Across 42 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$408
  • Grifols USA, LLC$270
  • GSK$258
  • Phathom Pharmaceuticals, Inc.$125
  • Novo Nordisk$104
  • AbbVie$88
  • plus $206 from 8 others

What the payments were for

  • Food & beverage$1,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,458 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$12,210
Medicare patients
75
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$41,540
TrulicityDulaglutide13$12,478
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$2,044
Bupropion XlBupropion Hcl35$1,125
Gabapentin50$1,029
Pantoprazole Sodium51$840
Levothyroxine Sodium58$725
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$724
Methylprednisolone124$662
Atorvastatin Calcium39$487
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav73$451
Rosuvastatin Calcium11$423
SynthroidLevothyroxine Sodium14$373
Pravastatin Sodium47$367
Albuterol Sulfate HfaAlbuterol Sulfate25$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$76$54,01849 claims
AbbVieSynthroid$88$37314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →